ELVN
Enliven Therapeutics Inc.
NASDAQ: ELVN · HEALTHCARE · BIOTECHNOLOGY
$42.40
-1.35% today
Updated 2026-04-29
Market cap
$2.58B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.83
Dividend yield
—
52W range
$15 – $49
Volume
1.2M
Enliven Therapeutics Inc. (ELVN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $10.22M | $7.71M | $33.30M | $90.84M | $113.33M | $83.30M | $271.87M | $325.76M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Current assets | $10.22M | $7.71M | $30.62M | $90.41M | $110.67M | $77.75M | $266.15M | $318.13M |
| Total liabilities | $1.49M | $1.83M | $4.38M | $6.41M | $6.47M | $160.12M | $25.96M | $15.91M |
| Current liabilities | $826000.00 | $1.83M | $4.20M | $6.25M | $5.75M | $9.71M | $25.89M | $15.91M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Shareholder equity | — | — | — | — | — | — | — | — |
| Retained earnings | $-19.95M | $-31.29M | $-54.75M | $-96.11M | $-45.20M | $-82.86M | $-154.45M | $-243.47M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — |